Signal amplification-based techniques

Nucleic Acid Testing for Human Disease

Volumn , Issue , 2016, Pages 19-64

  Hendricks, David A ^a   Comanor, Lorraine ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869193881     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (231)

1. Nolte FS. Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Adv Clin Chem 1998; 33: 201-235.
2. Wilber JC. Branched DNA for quantification of viral load. Immunol Invest 1997; 10 (1-2): 25-47.
3. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stempien M, Hoo B, Besemer D, Yeghiazarian T, Irvine B, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8 (5): 446-454.
4. Gleaves CA, Welle J, Campbell M, Elbeik T, Ng V, Taylor PE, Kuramoto K, Aceituno S, Lewalski E, Joppa B, et al. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J Clin Virol 2002; 25 (2): 205-216.
5. Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuramoto K, Ng V, Valdes R, Jr., Valsamakis A, et al. Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004; 42 (2): 563-569.
6. Yao JD, Beld MG, Oon LL, Sherlock CH, Germer J, Menting S, Se Thoe SY, Merrick L, Ziermann R, Surtihadi J, et al. Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J Clin Microbiol 2004; 42 (2): 800-806.
7. Collins ML, Irvine B, Tyner D, Fine E, Zayati C, Chang C, Horn T, Ahle D, Detmer J, Shen LP, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res 1997; 25 (15): 2979-2984.
8. Kenny D, Shen LP, Kolberg JA. Detection of viral infection and gene expression in clinical tissue specimens using branched DNA (bDNA) in situ hybridization. J Histochem Cytochem 2002; 50 (9): 1219-1227.
9. Horn T, Chang C-A, Collins ML. Hybridization properties of the 5-methyl-isocytidine/isoguanosine base pair in synthetic oligonucleotides. Tetrahedron Lett 1995; 36: 2033-2036.
10. Geyer CR, Battersby TR, Benner SA. Nucleobase pairing in expanded Watson-Crick-like genetic information systems. Structure (Camb) 2003; 11 (12): 1485-1498.
11. Bushnell S, Budde J, Catino T, Cole J, Derti A, Kelso R, Collins ML, Molino G, Sheridan P, Monahan J, et al. ProbeDesigner: for the design of probesets for branched DNA (bDNA) signal amplification assays. Bioinformatics 1999; 15 (5): 348-355.
12. Duck P, Alvarado-Urbina G, Burdick B, Collier B. Probe amplifier system based on chimeric cycling oligonucleotides. Biotechniques 1990; 9 (2): 142-149.
13. Harvey JJ, Lee SP, Chan EK, Kim JH, Hwang ES, Cha CY, Knutson JR, Han MK. Characterization and applications of CataCleave probe in real-time detection assays. Anal Biochem 2004; 333 (2): 246-255.
14. Fong WK, Modrusan Z, McNevin JP, Marostenmaki J, Zin B, Bekkaoui F. Rapid solid-phase immunoassay for detection of methicillin-resistant Staphylococcus aureus using cycling probe technology. J Clin Microbiol 2000; 38 (7): 2525-2529.
15. Hogrefe HH, Hogrefe RI, Walder RY, Walder JA. Kinetic analysis of Escherichia coli RNase H using DNA-RNA-DNA/DNA substrates. J Biol Chem 1990; 265 (10): 5561-5566.
16. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996; 23 (3): 707-730.
17. Iftner T, Villa LL. Human papillomavirus technologies. J Natl Cancer Inst Monogr 2003 (31): 80-88.
18. Niesters HG, Krajden M, Cork L, de Medina M, Hill M, Fries E, Osterhaus AD. A multicenter study evaluation of the Digene Hybrid Capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards. J Clin Microbiol 2000; 38 (6): 2150-2155.
19. Yuan HJ, Yuen MF, Wong DK, Sum SS, Lai CL. Clinical evaluation of the Digene Hybrid Capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels. J Clin Microbiol 2004; 42 (8): 3513-3517.
20. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998; 11 (3): 533-554.
21. Macartney M, Gane EJ, Portmann B, Williams R. Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods. Transplantation 1997; 63 (12): 1803-1807.
22. Lorincz A, Anthony J. Advances in HPV detection by Hybrid Capture. Pap Report 2001; 12 (6): 145-154.
23. de Arruda M, Lyamichev VI, Eis PS, Iszczyszyn W, Kwiatkowski RW, Law SM, Olson MC, Rasmussen EB. Invader technology for DNA and RNA analysis: principles and applications. Expert Rev Mol Diagn 2002; 2 (5): 487-496.
24. Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, Lai CL. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004; 40 (3): 727-737.
25. Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn 1999; 4 (4): 353-364.
26. Eis PS, Olson MC, Takova T, Curtis ML, Olson SM, Vener TI, Ip HS, Vedvik KL, Bartholomay CT, Allawi HT, et al. An invasive cleavage assay for direct quantitation of specific RNAs. Nat Biotechnol 2001; 19 (7): 673-676.
27. Qian X, Lloyd RV. Recent developments in signal amplification methods for in situ hybridization. Diagn Mol Pathol 2003; 12 (1): 1-13.
28. Hopman AH, Ramaekers FC, Speel EJ. Rapid synthesis of biotin-, digoxigenin-, trinitrophenyl-, and fluorochrome-labeled tyramides and their application for in situ hybridization using CARD amplification. J Histochem Cytochem 1998; 46 (6): 771-777.
29. Kohler A, Lauritzen B, Van Noorden CJ. Signal amplification in immunohistochemistry at the light microscopic level using biotinylated tyramide and nanogold-silver staining. J Histochem Cytochem 2000; 48 (7): 933-941.
30. Qian X, Bauer RA, Xu HS, Lloyd RV. In situ hybridization detection of calcitonin mRNA in routinely fixed, paraffin-embedded tissue sections: a comparison of different types of probes combined with tyramide signal amplification. Appl Immunohistochem Mol Morphol 2001; 9 (1): 61-69.
31. Francois P, Bento M, Vaudaux P, Schrenzel J. Comparison of fluorescence and resonance light scattering for highly sensitive microarray detection of bacterial pathogens. J Microbiol Methods 2003; 55 (3): 755-762.
32. Bao YP, Huber M, Wei TF, Marla SS, Storhoff JJ, Muller UR. SNP identification in unamplified human genomic DNA with gold nanoparticle probes. Nucleic Acids Res 2005; 33 (2): e15.
33. Storhoff JJ, Lucas AD, Garimella V, Bao YP, Muller UR. Homogeneous detection of unamplified genomic DNA sequences based on colorimetric scatter of gold nanoparticle probes. Nat Biotechnol 2004; 22 (7): 883-887.
34. Elghanian R, Storhoff JJ, Mucic RC, Letsinger RL, Mirkin CA. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 1997; 277 (5329): 1078-1081.
35. Kelley SO, Boon EM, Barton JK, Jackson NM, Hill MG. Single-base mismatch detection based on charge transduction through DNA. Nucleic Acids Res 1999; 27 (24): 4830-4837.
36. Kelley SO, Jackson NM, Hill MG, Barton JK. Long-range electron transfer through DNA films. Angew Chem Int Edn Engl 1999; 38: 941-945.
37. Boon EM, Ceres DM, Drummond TG, Hill MG, Barton JK. Mutation detection by electrocatalysis at DNA-modified electrodes. Nat Biotechnol 2000; 18 (10): 1096-1100.
38. Erratum in Nat Biotechnol 2000; 18 (12): 1318.
39. National Committee for Clinical Laboratory Standards. Quantitative Molecular Methods for Infectious Diseases: Approved Guideline. Document MM6-A. Wayne, PA. 2003.
40. Player AN, Shen LP, Kenny D, Antao VP, Kolberg JA. Single-copy gene detection using branched DNA (bDNA) in situ hybridization. J Histochem Cytochem 2001; 49 (5): 603-612.
41. Plummer TB, Sperry AC, Xu HS, Lloyd RV. In situ hybridization detection of low copy nucleic acid sequences using catalyzed reporter deposition and its usefulness in clinical human papillomavirus typing. Diagn Mol Pathol 1998; 7 (2): 76-84.
42. Yang H, Wanner IB, Roper SD, Chaudhari N. An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. J Histochem Cytochem 1999; 47 (4): 431-446.
43. van de Corput MP, Dirks RW, van Gijlswijk RP, van Binnendijk E, Hattinger CM, de Paus RA, Landegent JE, Raap AK. Sensitive mRNA detection by fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification. J Histochem Cytochem 1998; 46 (11): 1249-1259.
44. Holmes H, Davis C, Heath A, Hewlett I, Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001; 92 (2): 141-150.
45. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32 (3): 654-659.
46. Saldanha J, Heath A, Lelie N, Pisani G, Nubling M, Yu M. Calibration of HCV working reagents for NAT assays against the HCV international standard. Vox Sang 2000; 78 (4): 217-224.
47. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001; 80 (1): 63-71.
48. Brambilla D, Leung S, Lew J, Todd J, Herman S, Cronin M, Shapiro DE, Bremer J, Hanson C, Hillyer GV, et al. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol 1998; 36 (1): 311-314.
49. Klein D. Quantification using real-time PCR technology: applications and limitations. Trends Mol Med 2002; 8 (6): 257-260.
50. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C. 2002. http://consensus.nih.gov/cons/116/116cdc_intro.htm.
51. National Committee for Clinical Laboratory Standards. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. Document EP6-A. Wayne, PA. 2001.
52. Bartlett JG, Lane HC and Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. April 7, 2005. http://www.aidsinfo.nih.gov/guidelines.
53. Pellegrin I, Garrigue I, Binquet C, Chene G, Neau D, Bonot P, Bonnet F, Fleury H, Pellegrin JL. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol 1999; 37 (10): 3124-3132.
54. Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J, Dhumeaux D. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000; 85 (1-2): 11-21.
55. Caliendo AM, Yen-Lieberman B, Baptista J, Andersen J, Crumpacker C, Schuurman R, Spector SA, Bremer J, Lurain NS. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol 2003; 41 (8): 3509-3513.
56. Imbert-Marcille BM, Cantarovich D, Ferre-Aubineau V, Richet B, Soulillou JP, Billaudel S. Usefulness of DNA viral load quantification for cytomegalovirus disease monitoring in renal and pancreas/renal transplant recipients. Transplantation 1997; 63 (10): 1476-1481.
57. Human Retroviruses and AIDS 1997: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Korber B, Hahn B, Foley B, Mellors JW, Leitner T, Myers G, McCutchan F and Kuiken CL. Eds. Theoretical Biology and Biophysics Group, Los Alamos, NM: Los Alamos National Laboratory. 1997.
58. Human Retroviruses and AIDS 1996: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Myers G, Korber BT, Foley BT, Jeang K-T, Mellors JW, Wain-Hobson S, Eds., Theoretical Biology and Biophysics Group, Los Alamos, NM: Los Alamos National Laboratory. 1996.
59. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29 (2): 184-190.
60. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci USA 1993; 90 (17): 8234-8238.
61. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization; International Committee on Virus Taxonomy. Arch Virol 1998; 143 (12): 2493-2503.
62. Sablon E, Shapiro F. Hepatitis B and C genotyping: methodologies and implications for patient management. J Gastroenterol Hepatol 2004; 19: S329-S337.
63. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, Christopherson C, Spadoro JP, Young KK, Polonis V, McCutchan FE, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 1999; 37 (8): 2557-2263.
64. Jagodzinski LL, Wiggins DL, McManis JL, Emery S, Overbaugh J, Robb M, Bodrug S, Michael NL. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol 2000; 38 (3): 1247-1249.
65. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38 (11): 4171-4179.
66. Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, Tucker J, Urdea MS. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995; 226 (1): 120-129.
67. Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 1996; 34 (11): 2695-2701.
68. Lorincz A, Anthony J. A system for nucleic acid detection by signal amplification technology, in Van Dyke K, Van Dyke C, Woodfork K, Eds., Luminescence Biotechnology: Instruments and Applications. Boca Raton, FL: CRC Press. 2002.
69. Oliver M, Chuang LM, Chang MS, Chen YT, Pei D, Ranade K, de Witte A, Allen J, Tran N, Curb D, et al. High-throughput genotyping of single nucleotide polymorphisms using new biplex Invader technology. Nucleic Acids Res 2002; 30 (12): E53.
70. Modrusan Z, Marlowe C, Wheeler D, Pirseyedi M, Bryan RN. CPT-EIA assays for the detection of vancomycin-resistant vanA and vanB genes in enterococci. Diagn Microbiol Infect Dis 2000; 37 (1): 45-50.
71. Merlino J, Rose B, Harbour C. Rapid detection of non-multidrug-resistant and multidrug-resistant methicillin-resistant Staphylococcus aureus using cycling probe technology for the mecA gene. Eur J Clin Microbiol Infect Dis 2003; 22 (5): 322-323.
72. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA; WHO Collaborative Study Group. Vox Sang 1999; 76 (3): 149-158.
73. Saldanha J, Heath A. Collaborative study to calibrate hepatitis C virus genotypes 2-6 against the HCV International Standard 96/790 (genotype 1). Vox Sang 2003; 84 (1): 20-27.
74. European Association for the Study of the Liver. Consensus Statement. International Consensus Conference on Hepatitis C. Paris, February 1999. J Hepatol 1999; 30 (5): 956-961.
75. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor hepatitis C virus (HCV) monitor, Version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol 2002; 40 (3): 768-773.
76. Germer JJ, Heimgartner PJ, Ilstrup DM, Harmsen WS, Jenkins GD, Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40 (2): 495-500.
77. Trimoulet P, Halfon P, Pohier E, Khiri H, Chene G, Fleury H. Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40 (6): 2031-2036.
78. Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, Boom R. Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 2002; 40 (3): 788-793.
79. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272 (5265).
80. Erratum in Science 1997; 275 (5296): 14.
81. Mellors JW, Kingsley LA, Rinaldo CR, Jr., Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122 (8): 573-579.
82. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
83. Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour HH, Jr. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 2002; 30 (2): 154-158.
84. Muir D, White D, King J, Verlander N, Pillay D. Predictive value of the ultrasensitive HIV viral load assay in clinical practice. J Med Virol 2000; 61 (4): 411-416.
85. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danner S, Boucher C, Molla A, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12 (5): F9-F14.
86. Pancholi P, Wu F, Della-Latta P. Rapid detection of cytomegalovirus infection in transplant patients. Expert Rev Mol Diagn 2004; 4 (2): 231-242.
87. Whitley RJ. Cytomegalovirus and HIV: inextricably entwined pathogens. Lancet 2004; 363 (9427): 2101-2102.
88. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34 (6): 1225-1241.
89. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2 (2): 87-106.
90. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39 (3): 857-861.
91. Brook MG, Gilson R, Wilkins EL. BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med 2003; 4l Suppl 1: 42-51.
92. Soriano V, Miro JM, Garcia-Samaniego J, Torre-Cisneros J, Nunez M, del Romero J, Martin-Carbonero L, Castilla J, Iribarren JA, Quereda C, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11 (1): 2-17.
93. Weiss J, Wu H, Farrenkopf B, Schultz T, Song G, Shah S, Siegel J. Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard. J Clin Virol 2004; 30 (1): 86-93.
94. Pichoud C, Berby F, Stuyver L, Petit MA, Trepo C, Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000; 32 (2): 307-316.
95. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998; 28 (6): 1702-1706.
96. Anand BS, Velez M. Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. World J Gastroenterol 2004; 10 (16): 2409-2411.
97. Beld M, Penning M, van Putten M, van den Hoek A, Damen M, Klein MR, Goudsmit J. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94 (4): 1183-1191.
98. Bayer Corporation. VERSANT HCV RNA 3.0 Assay (bDNA). Package Insert. 2003.
99. Comanor L, Hendricks D. Hepatitis C virus RNA tests: performance attributes and their impact on clinical utility. Expert Rev Mol Diagn 2003; 3 (6): 689-702.
100. Jungkind D. Automation of laboratory testing for infectious diseases using the polymerase chain reaction: our past, our present, our future. J Clin Virol 2001; 20 (1-2): 1-6.
101. Abbott Laboratories. LCx HCV RNA Quantitative. Package Insert. 2003.
102. National Genetics Institute. Determination of analytical sensitivity of multiplexed and non-multiplexed NGI UltraQual RT PCR assays for the detection of HCV RNA in plasma pools. Product Licensure Application, 1999.
103. Barbeau JM, Goforth J, Caliendo AM, Nolte FS. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J Clin Microbiol 2004; 42 (8): 3739-3746.
104. Consensus Conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002; 26 (2): B303-B320.
105. Obiso R, Lorincz A. Digene Corporation. Pharmacogenomics 2004; 5 (1): 129-132.
106. Lorincz AT. Screening for cervical cancer: new alternatives and research. Salud Publica Mex 2003; 45; Suppl 3: S376-S387.
107. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84 (12): 1616-1623.
108. ACOG Practice Bulletin 45. Clinical management guidelines for obstetrician-gynecologists. Cervical cytology screening (replaces Committee Opinion 152, March 1995). Obstet Gynecol 2003; 102 (2): 417-427.
109. Chopra KF, Tyring SK. The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Arch Dermatol 1997; 133 (5): 629-633.
110. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1998; 47 (RR-1): 1-111.
111. Bignell CJ. European guideline for the management of gonorrhoea. Int J STD AIDS 2001; 12; Suppl 3: 27-29.
112. Stary A. European guideline for the management of chlamydial infection. Int J STD AIDS 2001; 12; Suppl 3: 30-33.
113. Myerow S, Lee M, Arruda J, Shen L-P, Madej R, Collins M, Miner R, McMullen D, Drew WL, Kolberg J. Development of a branched DNA assay with improved sensitivity for monitoring CMV viral load in immunocompromised patients. Annual Molecular Virology Workshop and Clinical Virology Symposium, Clearwater, FL, 1997.
114. Digene Corporation. Hybrid Capture II HBV DNA Test. Package Insert. 2004.
115. Digene Corporation. Hybrid Capture System CMV DNA Test (Version 2.0). Package Insert. 2002.
116. Wattanamano P, Clayton JL, Kopicko JJ, Kissinger P, Elliot S, Jarrott C, Rangan S, Beilke MA. Comparison of three assays for cytomegalovirus detection in AIDS patients at risk for retinitis. J Clin Microbiol 2000; 38 (2): 727-732.
117. Modarress KJ, Cullen AP, Jaffurs WJ, Sr., Troutman GL, Mousavi N, Hubbard RA, Henderson S, Lorincz AT. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in swab specimens by the Hybrid Capture II and PACE 2 nucleic acid probe tests. Sex Transm Dis 1999; 26 (5): 303-308.
118. van der Pol B, Williams JA, Smith NJ, Batteiger BE, Cullen AP, Erdman H, Edens T, Davis K, Salim-Hammad H, Chou VW, et al. Evaluation of the Digene Hybrid Capture II assay with the rapid capture system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2002; 40 (10): 3558-3564.
119. Cullen AP, Long CD, Lorincz AT. Rapid detection and typing of herpes simplex virus DNA in clinical specimens by the Hybrid Capture II signal amplification probe test. J Clin Microbiol 1997; 35 (9): 2275-2278.
120. Zeuzem S. Overview of commercial HBV assay systems, in Hamatake RK, Lau JYN, Eds., Hepatitis B and D protocols, Vol. 1. Totowa, NJ: Humana Press; 2004. pp. 3-13.
121. Mazzulli T, Wood S, Chua R, Walmsley S. Evaluation of the Digene Hybrid Capture system for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virusinfected patients. J Clin Microbiol 1996; 34 (12): 2959-2962.
122. Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002; 76 (1): 41-47.
123. Chernoff DN, Miner RC, Hoo BS, Shen L-P, Kelso RJ, Jekic-McMullen D, Lalezari JP, Chou S, Drew WL, Kolberg JA. Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay. J Clin Microbiol 1997; 35 (11): 2740-2744.
124. Martinot M, Marcellin P, Boyer N, Detmer J, Pouteau M, Castelnau C, Degott C, Auperin A, Collins M, Kolberg J, et al. Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C. Ann Intern Med 1997; 126 (11): 874-881.
125. Pessoa MG, Terrault NA, Ferrell LD, Kim JP, Kolberg J, Detmer J, Collins ML, Yun AJ, Viele M, Lake JR, et al. Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation. Hepatology 1997; 25 (5): 1266-1270.
126. Charlton MR, Brandhagen D, Wiesner RH, Gross JB, Jr., Detmer J, Collins M, Kolberg J, Krom RA, Persing DH. Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? Transplantation 1998; 65 (1): 73-76.
127. Lau DT, Miller KD, Detmer J, Kolberg J, Herpin B, Metcalf JA, Davey RT, Hoofnagle JH. Hepatitis G virus and human immunodeficiency virus coinfection: response to interferon-therapy. J Infect Dis 1999; 180 (4): 1334-1337.
128. McHutchison JG, Nainan OV, Alter MJ, Sedghi-Vaziri A, Detmer J, Collins M, Kolberg J. Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA. Hepatology 1997; 26 (5): 1322-1327.
129. Pessoa MG, Terrault NA, Detmer J, Kolberg J, Collins M, Hassoba HM, Wright TL. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998; 27 (3): 877-880.
130. Brandhagen DJ, Gross JB, Jr., Poterucha JJ, Charlton MR, Detmer J, Kolberg J, Gossard AA, Batts KP, Kim WR, Germer JJ, et al. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol 1999; 94 (4): 1000-1005.
131. Kolbert CP, Arruda J, Varga-Delmore P, Zheng X, Lewis M, Kolberg J, Persing DH. Branched-DNA assay for detection of the mecA gene in oxacillin-resistant and oxacillin-sensitive staphylococci. J Clin Microbiol 1998; 36 (9): 2640-2644.
132. Zheng X, Kolbert CP, Varga-Delmore P, Arruda J, Lewis M, Kolberg J, Cockerill FR, Persing DH. Direct mecA detection from blood culture bottles by branched-DNA signal amplification. J Clin Microbiol 1999; 37 (12): 4192-4193.
133. Kolberg JA, Besemer DJ, Stempien MM, Urdea MS. The specificity of pilin DNA sequences for the detection of pathogenic Neisseria. Mol Cell Probes 1989; 3 (1): 59-72.
134. Urdea MS, Kolberg J, Clyne J, Running JA, Besemer D, Warner B, Sanchez-Pescador R. Application of a rapid non-radioisotopic nucleic acid analysis system to the detection of sexually transmitted disease-causing organisms and their associated antimicrobial resistances. Clin Chem 1989; 35 (8): 1571-1575.
135. Nargessi RD, Shimizu RM, Xu XM, Connolly J, Zamroud M, Collins ML, Kolberg J. Quantitation of progesterone receptor mRNA in breast carcinoma by branched DNA assay. Breast Cancer Res Treat 1998; 50 (1): 57-62.
136. Nargessi RD, Khabbaz NF, Xu XM, Zamroud M, Kolberg J, Collins ML. Quantitation of estrogen receptor mRNA in breast carcinoma by branched DNA assay. Breast Cancer Res Treat 1998; 50 (1): 47-55.
137. Shen LP, Sheridan P, Cao WW, Dailey PJ, Salazar-Gonzalez JF, Breen EC, Fahey JL, Urdea MS, Kolberg JA. Quantification of cytokine mRNA in peripheral blood mononuclear cells using branched DNA (bDNA) technology. J Immunol Methods 1998; 215 (1-2): 123-134.
138. Breen EC, Salazar-Gonzalez JF, Shen LP, Kolberg JA, Urdea MS, Martinez-Maza O, Fahey JL. Circulating CD8 T cells show increased interferon-gamma mRNA expression in HIV infection. Cell Immunol 1997; 178 (1): 91-98.
139. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42 (12): 2487-2494.
140. Salazar-Gonzalez JF, Martinez-Maza O, Aziz N, Kolberg JA, Yeghiazarian T, Shen LP, Fahey JL. Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection. Clin Immunol Immunopathol 1997; 84 (1): 36-45.
141. Wang J, Shen L, Najafi H, Kolberg J, Matschinsky FM, Urdea M, German M. Regulation of insulin preRNA splicing by glucose. Proc Natl Acad Sci USA 1997; 94 (9): 4360-4365.
142. Harris E, Detmer J, Dungan J, Doua F, White T, Kolberg JA, Urdea MS, Agabian N. Detection of Trypanosoma brucei spp. in human blood by a nonradioactive branched DNA-based technique. J Clin Microbiol 1996; 34 (10): 2401-2407.
143. Hartley DP, Klaassen CD. Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. Drug Metab Dispos 2000; 28 (5): 608-616. Erratum in Drug Metab Dispos 2000; 28 (8): 1007.
144. Erratum in Drug Metab Dispos 2000; 28 (8): 1007.
145. Dickinson Laing T, Mah DC, Poirier RT, Bekkaoui F, Lee WE, Bader DE. Genomic DNA detection using cycling probe technology and capillary gel electrophoresis with laser-induced fluorescence. Mol Cell Probes 2004; 18 (5): 341-348.
146. Tang T, Badal MY, Ocvirk G, Lee WE, Bader DE, Bekkaoui F, Harrison DJ. Integrated microfluidic electrophoresis system for analysis of genetic materials using signal amplification methods. Anal Chem 2002; 74 (4): 725-733.
147. Warnon S, Zammatteo N, Alexandre I, Hans C, Remacle J. Colorimetric detection of the tuberculosis complex using cycling probe technology and hybridization in microplates. Biotechniques 2000; 28 (6): 1152-1160.
148. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002; 22 (2): 121-126.
149. Norris S, Kosar Y, Donaldson N, Smith HM, Zolfino T, O'Grady JG, Muiesan P, Rela M, Heaton N. Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection. Transplantation 2002; 74 (4): 527-531.
150. Chemaly RF, Yen-Lieberman B, Chapman J, Reilly A, Bekele BN, Gordon SM, Procop GW, Shrestha N, Isada CM, Decamp M, et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005; 5 (3): 544-548.
151. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003; 127 (8): 946-949.
152. Drobacheff C, Dupont P, Mougin C, Bourezane Y, Challier B, Fantoli M, Bettinger D, Laurent R. Anal human papillomavirus DNA screening by Hybrid Capture II in human immunodeficiency viruspositive patients with or without anal intercourse. Eur J Dermatol 2003; 13 (4): 367-371.
153. Schachter J, Hook EW, 3rd, McCormack WM, Quinn TC, Chernesky M, Chong S, Girdner JI, Dixon PB, DeMeo L, Williams E, et al. Ability of the Digene Hybrid Capture II test to identify Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens. J Clin Microbiol 1999; 37 (11): 3668-3671.
154. Yehle CO, Patterson WL, Boguslawski SJ, Albarella JP, Yip KF, Carrico RJ. A solution hybridization assay for ribosomal RNA from bacteria using biotinylated DNA probes and enzyme-labeled antibody to DNA:RNA. Mol Cell Probes 1987; 1 (2): 177-193.
155. Lamoureux M, MacKay A, Messier S, Fliss I, Blais BW, Holley RA, Simard RE. Detection of Campylobacter jejuni in food and poultry viscera using immunomagnetic separation and microtitre hybridization. J Appl Microbiol 1997; 83 (5): 641-651.
156. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WEt, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126 (7): 1750-1758.
157. Cooksey RC, Holloway BP, Oldenburg MC, Listenbee S, Miller CW. Evaluation of the Invader assay, a linear signal amplification method, for identification of mutations associated with resistance to rifampin and isoniazid in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44 (5): 1296-1301.
158. Fors L, Lieder KW, Vavra SH, Kwiatkowski RW. Large-scale SNP scoring from unamplified genomic DNA. Pharmacogenomics 2000; 1 (2): 219-229.
159. Olson MC, Takova T, Chehak L, Curtis ML, Olson SM, Kwiatkowski RW. Invader assay for RNA quantitation. Methods Mol Biol 2004; 258: 53-69.
160. Neville M, Selzer R, Aizenstein B, Maguire M, Hogan K, Walton R, Welsh K, Neri B, de Arruda M. Characterization of cytochrome p450 2D6 alleles using the Invader™ system. Biotechniques 2002;32(suppl 2):S34-43.
161. Ryan D, Nuccie B, Arvan D. Non-PCR-dependent detection of the factor V Leiden mutation from genomic DNA using a homogeneous Invader microtiter plate assay. Mol Diagn 1999; 4 (2): 135-144.
162. Berggren WT, Takova T, Olson MC, Eis PS, Kwiatkowski RW, Smith LM. Multiplexed gene expression analysis using the invader RNA assay with MALDI-TOF mass spectrometry detection. Anal Chem 2002; 74 (8): 1745-1750.
163. Nakajima N, Ionescu P, Sato Y, Hashimoto M, Kuroita T, Takahashi H, Yoshikura H, Sata T. In situ hybridization AT-tailing with catalyzed signal amplification for sensitive and specific in situ detection of human immunodeficiency virus-1 mRNA in formalin-fixed and paraffin-embedded tissues. Am J Pathol 2003; 162 (2): 381-389.
164. Murakami T, Hagiwara T, Yamamoto K, Hattori J, Kasami M, Utsumi M, Kaneda T. A novel method for detecting HIV-1 by non-radioactive in situ hybridization: application of a peptide nucleic acid probe and catalysed signal amplification. J Pathol 2001; 194 (1): 130-135.
165. Kotronias D, Kapranos N. Detection of herpes simplex virus DNA in maternal breast milk by in situ hybridization with tyramide signal amplification. In Vivo 1999; 13 (6): 463-466.
166. Lizard G, Demares-Poulet MJ, Roignot P, Gambert P. In situ hybridization detection of single-copy human papillomavirus on isolated cells, using a catalyzed signal amplification system: GenPoint. Diagn Cytopathol 2001; 24 (2): 112-116.
167. Zerbini M, Cricca M, Gentilomi G, Venturoli S, Gallinella G, Musiani M. Tyramide signal amplification of biotinylated probe in dot-blot hybridization assay for the detection of parvovirus B19 DNA in serum samples. Clin Chim Acta 2000; 302 (1-2): 79-87.
168. Fijnvandraat AC, De Boer PA, Deprez RH, Moorman AF. Non-radioactive in situ detection of mRNA in ES cell-derived cardiomyocytes and in the developing heart. Microsc Res Tech 2002; 58 (5): 387-394.
169. Tsang YT, Chang YM, Lu X, Rao PH, Lau CC, Wong KK. Amplification of MGC2177, PLAG1, PSMC6P, and LYN in a malignant mixed tumor of salivary gland detected by cDNA microarray with tyramide signal amplification. Cancer Genet Cytogenet 2004; 152 (2): 124-128.
170. Denef VJ, Park J, Rodrigues JL, Tsoi TV, Hashsham SA, Tiedje JM. Validation of a more sensitive method for using spotted oligonucleotide DNA microarrays for functional genomics studies on bacterial communities. Environ Microbiol 2003; 5 (10): 933-943.
171. Wang D, Zhu L, Jiang D, Ma X, Zhou Y, Cheng J. Direct detection of 16S rRNA using oligonucleotide microarrays assisted by base stacking hybridization and tyramide signal amplification. J Biochem Biophys Methods 2004; 59 (2): 109-120.
172. Bakermans C, Madsen EL. Detection in coal tar waste-contaminated groundwater of mRNA transcripts related to naphthalene dioxygenase by fluorescent in situ hybridization with tyramide signal amplification. J Microbiol Methods 2002; 50 (1): 75-84.
173. Pernthaler A, Pernthaler J, Amann R. Fluorescence in situ hybridization and catalyzed reporter deposition for the identification of marine bacteria. Appl Environ Microbiol 2002; 68 (6): 3094-3101.
174. Sekar R, Pernthaler A, Pernthaler J, Warnecke F, Posch T, Amann R. An improved protocol for quantification of freshwater Actinobacteria by fluorescence in situ hybridization. Appl Environ Microbiol 2003; 69 (5): 2928-2935.
175. West NJ, Schonhuber WA, Fuller NJ, Amann RI, Rippka R, Post AF, Scanlan DJ. Closely related Prochlorococcus genotypes show remarkably different depth distributions in two oceanic regions as revealed by in situ hybridization using 16S rRNA-targeted oligonucleotides. Microbiology 2001; 147 (Pt 7): 1731-1744.
176. Zhang Z, Kitching P. A sensitive method for the detection of foot and mouth disease virus by in situ hybridisation using biotin-labelled oligodeoxynucleotides and tyramide signal amplification. J Virol Methods 2000; 88 (2): 187-192.
177. Berent LM, Messick JB, Cooper SK, Cusick PK. Specific in situ hybridization of Haemobartonella felis with a DNA probe and tyramide signal amplification. Vet Pathol 2000; 37 (1): 47-53.
178. Fujino Y, Satoh H, Hisasue M, Masuda K, Ohno K, Tsujimoto H. Detection of the integrated feline leukemia viruses in a cat lymphoid tumor cell line by fluorescence in situ hybridization. J Hered 2003; 94 (3): 251-255.
179. Acar H, Copeland NG, Gilbert DJ, Jenkins NA, Largaespada DA. Detection of integrated murine leukemia viruses in a mouse model of acute myeloid leukemia by fluorescence in situ hybridization combined with tyramide signal amplification. Cancer Genet Cytogenet 2000; 121 (1): 44-51.
180. Schad A, Fahimi HD, Volkl A, Baumgart E. Expression of catalase mRNA and protein in adult rat brain: detection by nonradioactive hybridization with signal amplification by catalyzed reporter deposition (ISH-CARD) and immunohistochemistry (IHC)/immunofluorescence (IF). J Histochem Cytochem 2003; 51 (6): 751-760.
181. Divi RL, Dragan YP, Pitot HC, Poirier MC. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 2001; 22 (10): 1693-1699.
182. Khrustaleva LI, Kik C. Localization of single-copy T-DNA insertion in transgenic shallots (Allium cepa) by using ultra-sensitive FISH with tyramide signal amplification. Plant J 2001; 25 (6): 699-707.
183. Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, et al. Daily low-dose subcutaneous interleukin-2 added to single-or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr 2004; 36 (1): 576-587.
184. Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). J Antimicrob Chemother 2004; 53 (3): 501-505.
185. Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon EDMB, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, et al. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr 2004; 36 (2): 693-701.
186. Ayouba A, Tene G, Cunin P, Foupouapouognigni Y, Menu E, Kfutwah A, Thonnon J, Scarlatti G, Monny-Lobe M, Eteki N, et al. Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2003; 34 (3): 274-280.
187. Yeghiazarian T, Zhao Y, Read SE, Kabat W, Li X, Hamren S, Sheridan PJ, Wilber JC, Chernoff DN, Yogev R. Quantification of human immunodeficiency virus type 1 (HIV-1) RNA levels in plasma using small volume format branched DNA assays. J Clin Microbiol 1998; 36: 2096-2098.
188. Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots K, Chernoff D, Winkler C, O'Brien SJ. Effects of plasma HIV RNA, CD4+ T lymphocytes and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs: Hemophilia Growth and Development Study. J Acquir Immune Defic Syndr 1999; 21 (4): 317-325.
189. Flood J, Drew WL, Miner R, Jekic-McMullen D, Shen LP, Kolberg J, Garvey J, Follansbee S, Poscher M. Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays. J Infect Dis 1997; 176 (2): 348-352.
190. O'Sullivan CE, Drew WL, McMullen DJ, Miner R, Lee JY, Kaslow RA, Lazar JG, Saag MS. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180 (3): 847-849.
191. Barrett-Muir W, Breuer J, Millar C, Thomas J, Jeffries D, Yaqoob M, Aitken C. CMV viral load measurements in whole blood and plasma: which is best following renal transplantation? Transplantation 2000; 70 (1): 116-119.
192. Hebart H, Wuchter P, Loeffler J, Gscheidle B, Hamprecht K, Sinzger C, Jahn G, Dietz K, Kanz L, Einsele H. Evaluation of the Murex CMV DNA Hybrid Capture assay (Version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001; 28 (2): 213-218.
193. Bhorade SM, Sandesara C, Garrity ER, Vigneswaran WT, Norwick L, Alkan S, Husain AN, McCabe MA, Yeldandi V. Quantification of cytomegalovirus (CMV) viral load by the Hybrid Capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 2001; 20 (9): 928-934.
194. Perinatal HIV Guidelines Working Group. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, February 24, 2005. http://aidsinfo.nih.gov.
195. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123 (6): 1831-1838.
196. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, Poupon R. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34 (3): 573-577.
197. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9 (1): 49-56.
198. Yuen MF, Yuan HJ, Sablon E, Wong DK, Chan AO, Wong BC, Lai CL. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 2004; 42 (9): 3932-3936.
199. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, et al. Clinical trial of lamivudine in children with chronic hepatitis B. New Engl J Med 2002; 346 (22): 1706-1713.
200. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. New Engl J Med 2002; 347 (3): 168-174.
201. Zampino R, Marrone A, Mangoni ED, Santarpia L, Sica A, Tripodi MF, Utili R, Ruggiero G, Adinolfi LE. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment. J Med Virol 2004; 73 (1): 33-37.
202. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28 (1): 27-33.
203. Dai CY, Yu ML, Chuang WL, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001; 16 (6): 636-640.
204. Yates SC, Hafez M, Beld M, Lukashov VV, Hassan Z, Carboni G, Khaled H, McMorrow M, Attia M, Goudsmit J. Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. Am J Trop Med Hyg 1999; 60 (4): 714-720.
205. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IV. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6 (5): 387-395.
206. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46 (6): 1734-1740.
207. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10 (4): 294-297.
208. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 2004; 16 (11): 1213-1218.
209. Smith JP, Riley TR, 3rd, Bingaman S, Mauger DT. Amantadine therapy for chronic hepatitis C: a dose escalation study. Am J Gastroenterol 2004; 99 (6): 1099-1104.
210. Tassopoulos NC, Tsantoulas D, Raptopoulou M, Vassiliadis T, Kanatakis S, Paraskevas E, Vafiadis I, Avgerinos A, Tzathas C, Manolakopoulos S, et al. A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1. J Viral Hepat 2003; 10 (3): 189-196.
211. Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002; 14 (8): 833-840.
212. Lunel F, Veillon P, Fouchard-Hubert I, Loustaud-Ratti V, Abergel A, Silvain C, Rifflet H, Blanchi A, Causse X, Bacq Y, et al. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. J Hepatol 2003; 39 (5): 826-833.
213. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21 (6): 435-440.
214. Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG, Ng KW, Gretch DR, Jensen DM. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001; 71 (2): 261-266.
215. Beckebaum S, Cicinnati VR, Zhang X, Malago M, Dirsch O, Erim Y, Frilling A, Broelsch CE, Gerken G. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study. Transplant Proc 2004; 36 (5): 1489-1491.
216. Castera L, Morice Y, Grando V, Bon C, Deny P, Roulot D. Hepatitis C virus genotype 4: epidemiology and treatment. Gastroenterol Clin Biol 2003; 27 (6-7): 596-604.
217. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140 (5): 370-381.
218. Kamal S, El Tawil A, He Q, Koziel M, Ismail A, Raseneck J, El Sayed K, Hafez A, Madwar M. Peginterferon alpha 2b and ribavirin combination therapy in chronic hepatitis C genotype 4: impact of treatment duration on sustained virologic response (Abstr.). Hepatology 2004; 40 (Suppl 1): 322A.
219. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40 (6): 993-999.
220. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 2004; 351 (5): 438-450.
221. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92 (5): 397-402.
222. Pelletier F, Drobacheff-Thiebaut C, Aubin F, Venier AG, Mougin C, Laurent R. Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients. Ann Dermatol Venereol 2004; 131 (11): 947-951.
223. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams AR. A longitudinal study of HPV detection and cervical pathology in HIV infected women. Sex Transm Infect 2000; 76 (4): 257-261.
224. Lillo FB, Lodini S, Ferrari D, Stayton C, Taccagni G, Galli L, Lazzarin A, Uberti-Foppa C. Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. Clin Infect Dis 2005; 40 (3): 451-457.
225. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T, Ngwalle S, Munjoma M, Shah KV. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000; 85 (2): 206-210.
226. Darwin LH, Cullen AP, Crowe SR, Modarress KJ, Willis DE, Payne WJ. Evaluation of the Hybrid Capture 2 CT/GC DNA tests and the GenProbe PACE 2 tests from the same male urethral swab specimens. Sex Transm Dis 2002; 29 (10): 576-580.
227. da Silva CS, Adad SJ, Hazarabedian de Souza MA, Macedo-Barcelos AC, Sarreta-Terra AP, Candido-Murta EF. Increased frequency of bacterial vaginosis and Chlamydia trachomatis in pregnant women with human papillomavirus infection. Gynecol Obstet Invest 2004; 58 (4): 189-193.
228. de Lima Soares V, de Mesquita AM, Cavalcante FG, Silva ZP, Hora V, Diedrich T, de Carvalho Silva P, de Melo PG, Dacal AR, de Carvalho EM, et al. Sexually transmitted infections in a female population in rural north-east Brazil: prevalence, morbidity and risk factors. Trop Med Int Health 2003; 8 (7): 595-603.
229. Baldwin SB, Djambazov B, Papenfuss M, Abrahamsen M, Denman C, Guernsey de Zapien J, Ortega L, Navarro Henze JL, Hunter J, Rojas M, et al. Chlamydial infection in women along the US-Mexico border. Int J STD AIDS 2004; 15 (12): 815-821.
230. Giuliano AR, Denman C, Guernsey de Zapien J, Navarro Henze JL, Ortega L, Djambazov B, Mendez Brown de Galaz E, Hatch K. Design and results of the USA-Mexico border human papillomavirus (HPV), cervical dysplasia, and Chlamydia trachomatis study. Rev Panam Salud Publica 2001; 9 (3): 172-181.
231. Ishi K, Suzuki F, Saito A, Kubota T. Prevalence of human papillomavirus, Chlamydia trachomatis, and Neisseria gonorrhoeae in commercial sex workers in Japan. Infect Dis Obstet Gynecol 2000; 8 (5-6): 235-239.